CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 50 enrolled
Drug / intervention
Stereotactic Body Radiation Therapy (SBRT)radiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01357525
NCT01357525N/ACompleted
CompareCT.gov

SBRT for Close or Positive Margins After Resection of Pancreatic Adenocarcinoma A Prospective Evaluation in Select Patients With Resected Pancreas Cancer

David A. Clump, MD, PhD·interventional·Posted May 20, 2011·Updated Nov 24, 2021

In Brief

A clinical study evaluating Stereotactic Body Radiation Therapy (SBRT) for Adenocarcinoma of the Pancreas. Completed, enrolled 50 participants across 1 site.

Detailed Summary

The current study seeks to further investigate the impact of Stereotactic Body Radiation Therapy following pancreatic resection with a close or positive margin. The investigators hope to improve local control, and through the use of a shortened treatment schedule, allow patients to begin systemic therapy earlier.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdenocarcinoma of the Pancreas
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMay 20, 2011
Enrollment StartFeb 6, 2013
Primary CompletionApr 1, 2018
Study CompletionJun 1, 2018
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 15.1 years ago

Interventions

Stereotactic Body Radiation Therapy (SBRT)radiation

An SBRT plan will be created by a medical physicist based on the PTV contoured on the CT scan. The plan will be to deliver fractionated SBRT to the isodose line best encompassing the PTV: 12 Gy x 3 fractions (36 Gy total)